Overview
Aged Garlic Extract (AGE) is a standardized dietary supplement created through prolonged cold aging of raw garlic, a process that transforms harsh sulfur compounds into stable, bioavailable organosulfur compounds. The primary bioactive ingredient, S-allylcysteine (SAC), along with S-allylmercaptocysteine (SAMC), forms the foundation of AGE's therapeutic effects. Unlike raw garlic or allicin-based supplements, AGE is odorless, tasteless, and well-tolerated, making it suitable for long-term daily supplementation.
AGE has become one of the most studied garlic supplements, with robust evidence supporting its role in cardiovascular health, immune modulation, and inflammatory marker reduction. The supplement is widely available over-the-counter, affordable (typically $12–$35 per month), and carries an excellent safety profile for most populations when used at recommended doses.
How It Works: Mechanism of Action
Aged Garlic Extract exerts its health benefits through multiple, interconnected biological pathways:
Cardiovascular Effects
The primary mechanism for AGE's heart-protective benefits involves several simultaneous processes. S-allylcysteine inhibits HMG-CoA reductase activity, an enzyme critical for cholesterol synthesis, thereby reducing LDL cholesterol levels. AGE also reduces oxidative stress by upregulating Nrf2-dependent antioxidant enzymes, including glutathione-S-transferase and superoxide dismutase. These enzymes neutralize harmful free radicals that damage blood vessel walls.
AGE modulates nitric oxide synthase, an enzyme that increases nitric oxide production. Nitric oxide promotes endothelial vasodilation—the relaxation and widening of blood vessels—which improves blood flow and reduces blood pressure. This mechanism is particularly important for hypertension management.
Additionally, organosulfur compounds in AGE inhibit platelet aggregation by interfering with thromboxane A2 synthesis, contributing to mild anticoagulant and antiplatelet properties that support healthy circulation.
Anti-Inflammatory and Immunomodulatory Effects
AGE demonstrates potent anti-inflammatory activity by suppressing NF-κB signaling, a master regulator of inflammatory gene expression. This suppression reduces production of pro-inflammatory cytokines, particularly TNF-α and IL-6, which are central to chronic inflammation and aging-related diseases.
Through these mechanisms, AGE enhances immune cell function, particularly natural killer (NK) cells and gamma-delta T cells, which patrol the body for pathogens and abnormal cells.
Antioxidant Protection
The upregulation of endogenous antioxidant systems makes AGE a powerful reducer of oxidative stress, a root cause of cardiovascular disease, neurodegeneration, and accelerated aging.
Evidence by Health Goal
Heart Health — Tier 4: Strong Evidence
AGE demonstrates the most robust evidence for cardiovascular benefits among all health outcomes studied.
Blood Pressure Reduction: Meta-analyses consistently show systolic blood pressure reductions of 4.03 mmHg (95% CI: -6.87 to -1.20 mmHg) across nine randomized controlled trials with 584 hypertensive participants. In responder subgroups—individuals who show a clinically meaningful response to supplementation—systolic reductions reached 5.0 mmHg on average. In one study, responders experienced even more dramatic improvements, with some achieving 11.5 mmHg systolic reductions. These effects were accompanied by improvements in central hemodynamics, including reduced pulse-wave velocity and arterial stiffness.
Low-Dose SAC Effects: Even at low doses of 0.25 mg/day of isolated S-allylcysteine, hypertensive patients receiving background antihypertensive medication showed modest but significant reductions in systolic blood pressure (1.8 mmHg; 95% CI 0.7–4.1) and diastolic pressure (1.5 mmHg; 95% CI 0.3–3.0) over 12 weeks.
Cardiovascular Calcification: In a meta-analysis of 49 randomized controlled trials involving 9,901 total participants, aged garlic extract was the only intervention to consistently attenuate cardiovascular calcification, a major pathological feature of aging and atherosclerosis.
Cholesterol and Metabolic Markers: Moderately hypercholesterolemic men receiving 7.2g/day of AGE for six months achieved total serum cholesterol reductions of 6.1–7.0% and systolic blood pressure reductions of 5.5%.
Anti-Inflammation — Tier 3: Probable Efficacy
Multiple human randomized controlled trials and meta-analyses confirm AGE's ability to reduce key inflammatory markers.
C-Reactive Protein (CRP): A meta-analysis of 17 RCTs found significant CRP reduction with AGE supplementation (p < 0.05). In coronary artery disease patients, the effect size was substantial: CRP reduced with an SMD (standardized mean difference) of -0.59 (95% CI -0.92 to -0.25; p = 0.0007).
TNF-α Reduction: TNF-α, a central pro-inflammatory cytokine, was significantly reduced in multiple trials. In obese adults receiving 3.6 g/day of AGE for six weeks, TNF-α decreased significantly (p = 0.05). A meta-analysis in cardiovascular disease patients reported TNF-α reduction with an SMD of -0.59.
IL-6 Findings: Results for interleukin-6 are more mixed. One meta-analysis found no significant effect on IL-6, while another in coronary artery disease patients reported a substantial reduction (SMD = -1.08; 95% CI -2.17 to 0.01; p = 0.05). In obese adults, IL-6 decreased significantly after six weeks (p = 0.04).
The variability in IL-6 effects likely reflects differences in participant populations, AGE dosages, and study duration.
Immune Support — Tier 3: Probable Efficacy
AGE enhances immune function through multiple mechanisms demonstrated in human trials.
NK Cell and γδ-T Cell Activation: In a double-blind randomized controlled trial with 120 healthy adults, AGE supplementation at 2.56 g/day for 90 days significantly enhanced natural killer cell and gamma-delta T cell proliferation and activation after 45 days of treatment. These immune cells are critical for viral defense and surveillance of abnormal cells.
Cold and Flu Severity: The same trial showed reduced severity of cold and flu symptoms and fewer days of suboptimal function in the AGE group, though the overall incidence of illness did not change significantly. This suggests AGE may reduce symptom severity rather than preventing infection entirely.
Inflammatory Marker Reduction in Obese Adults: Obese adults receiving 3.6 g/day AGE showed significantly reduced IL-6 (p = 0.04) and TNF-α (p = 0.05) after six weeks in a double-blind trial with 51 participants.
Fat Loss and Metabolic Health — Tier 3: Probable Efficacy
Evidence supports AGE's role in weight management and metabolic improvements, though effects are modest.
Body Weight Reduction: Postmenopausal women receiving 80 mg/day AGE for 12 weeks showed significant decreases in body weight compared to placebo in a randomized controlled trial (n = 30).
Inflammatory Marker Improvement: In obese adults, AGE reduced serum IL-6 (p = 0.04) and TNF-α (p = 0.05) after six weeks, suggesting reduction in metabolic inflammation that drives obesity and insulin resistance.
Visceral Fat and Metabolic Parameters: Animal studies demonstrate that AGE combined with exercise produces additive effects on visceral fat and liver weight reduction in high-fat diet-induced obese rats (p < 0.001), with combined treatment superior to either intervention alone.
Adiponectin Elevation: In metabolic syndrome patients, 12 weeks of AGE treatment increased plasma adiponectin levels (p = 0.027) in a double-blind, crossover randomized controlled trial with 31 participants. Adiponectin is an adipokine that improves insulin sensitivity and reduces cardiovascular risk.
Athletic Performance — Tier 3: Probable Efficacy
Limited but promising evidence suggests AGE enhances aerobic fitness and vascular function in athletes.
VO2max and Lactate Threshold: Middle-aged endurance athletes receiving 1.2–2.4 g/day of Kyolic aged garlic extract for 12 weeks showed improved aerobic fitness markers, including increased VO2max and lactate threshold, with reduced arterial stiffness (n = 75).
Microvascular Reactivity: In older adults (n = 28), a single 2.4g dose of AGE significantly accelerated microvascular reactivity compared to placebo. The StO2 upslope (a marker of oxygen tissue saturation recovery) was 1.01±0.37 %·s⁻¹ with AGE versus 0.83±0.35 %·s⁻¹ with placebo (p < 0.001, effect size d = 0.50), indicating faster oxygen delivery to working muscles.
Skin, Wound Healing & Microcirculation — Tier 3: Probable Efficacy
AGE improves microvascular function and tissue perfusion, supporting wound healing and potentially benefiting skin health indirectly.
Post-Occlusive Reactive Hyperemia (PORH): In 93 atherosclerosis patients, AGE at 2400 mg/day increased post-occlusive reactive hyperemia—a measure of microvascular function—by 21.6% (95% CI 3.2%–40.0%, p < 0.05) over 12 months compared to placebo.
Cutaneous Vascular Conductance: In the same cohort, cutaneous vascular conductance with acetylcholine iontophoresis (a measure of endothelial function) increased by 21.4% (95% CI 3.4%–39.4%, p < 0.05).
Microcirculation in High-Risk Patients: In 122 patients with a Framingham Risk Score ≥ 10, AGE increased microcirculation with a mean percent change of 102.64% versus 78.62% in the placebo group over 12 months.
Longevity and Aging Markers — Tier 3: Probable Efficacy
AGE shows consistent benefits for cardiovascular health markers associated with healthy aging, though direct longevity studies have not been conducted.
Cardiovascular Calcification Attenuation: In a comprehensive meta-analysis of 49 randomized controlled trials covering 9,901 participants, aged garlic extract was the only intervention to consistently attenuate cardiovascular calcification, a hallmark of vascular aging.
Blood Pressure in Controlled Hypertensives: Even in patients already receiving antihypertensive medication, low-dose SAC (0.25 mg/day) produced measurable systolic (1.8 mmHg) and diastolic (1.5 mmHg) blood pressure reductions over 12 weeks.
Cognition and Neuroprotection — Tier 2: Plausible but Unproven
AGE demonstrates strong neuroprotective effects in animal models, but human clinical evidence is lacking.
Stroke Prevention in Rats: In rodent models of cerebral ischemia, AGE reduced infarct area by 54.8% and neurological deficits by 61.6% when administered at reperfusion onset. AGE prevented ischemia-induced increases in the oxidative stress marker 8-OHdG by 77.8% and reduced TNF-α by 76.6% in rat brain tissue.
Mechanistic Support: These animal studies suggest AGE's antioxidant and anti-inflammatory mechanisms could protect against cognitive decline, but no human clinical trials demonstrating cognitive improvement have been completed.
Energy and Aerobic Performance — Tier 2: Plausible but Unproven
Limited human evidence and primarily animal mechanistic studies support potential energy benefits.
VO2max Improvements: The aforementioned study in endurance athletes showed improved aerobic fitness markers with AGE supplementation, suggesting enhanced oxygen utilization and energy metabolism.
Metabolic and Vascular Mechanisms: Animal studies demonstrate AGE's ability to improve blood flow and oxygen delivery, mechanistic pathways that could support energy production, but direct human energy measurements are absent.
Sexual Health and Male Aging — Tier 2: Plausible but Unproven
One small open-label human study provides limited evidence for AGE's role in sexual function.
Erectile Function: In an open-label trial (n = 24), men receiving aged garlic extract (in a 6-ingredient formula) showed significantly improved erectile function as measured by the International Index of Erectile Function-5 (IIEF-5) score (p = 0.02 for group × month interaction) over six months.
Aging Symptoms: The Aging Males' Symptoms scale decreased more rapidly in the aged garlic extract group compared to a Kampo control group (p < 0.05, n = 49).
Limitations: Open-label design and small sample sizes limit confidence; additional blinded, placebo-controlled trials are needed.
Hormonal Balance — Tier 3: Probable Efficacy
AGE shows modest benefits for hormone-related markers, particularly in metabolic health.
Adiponectin Elevation: As mentioned above, AGE increased plasma adiponectin levels in metabolic syndrome patients (p = 0.027), suggesting improved insulin sensitivity and metabolic health.
Cholesterol Management: Moderately hypercholesterolemic men achieved 6.1–7.0% reductions in total serum cholesterol and 5.5% reductions in systolic blood pressure after six months of AGE 7.2g/day supplementation.
Gut Health — Tier 3: Probable Efficacy
AGE modulates the gut microbiota and supports intestinal health through prebiotic mechanisms.
Microbiota Diversity: In a 12-week randomized controlled trial with 49 participants, aged garlic extract significantly improved gut microbiota diversity and reduced central blood pressure and arterial stiffness. Trends toward TNF-α and IL-6 reduction were observed but did not reach statistical significance.
Prebiotic Properties: A meta-analysis of garlic supplements confirmed prebiotic properties that increase gut microbial richness and diversity in hypertensive subjects across multiple trials.
Liver Health — Tier 2: Plausible but Unproven
Human evidence for liver health is limited; most supportive data comes from animal models and immune studies.
NK Cell Enhancement in Cancer Patients: In 50 advanced cancer patients (42 with liver cancer), AGE significantly increased NK cell activity and NK cell number after six months compared to placebo; however, no improvement in quality of life was observed.
Liver Weight in Animal Models: In high-fat diet-fed rats, AGE combined with exercise reduced liver weight gain by approximately 25–30% compared to high-fat diet alone.
Joint Health and Musculoskeletal Support — Tier 1: Insufficient Evidence
No human clinical trials for joint health efficacy exist in the available literature. While reviews discuss garlic's theoretical promise for knee osteoarthritis and rheumatoid arthritis, no specific efficacy data or effect sizes are available.
Muscle Growth and Strength — Tier 1: No Evidence
AGE has not been studied for muscle hypertrophy or strength gains in humans. All available evidence focuses on cardiovascular health, immune function, and neuroprotection.
Mood and Stress — Tier 2: Plausible but Unproven
While AGE reduces inflammatory cytokines and oxidative stress—mechanisms theoretically relevant to mood and stress resilience—no human studies have directly measured mood or stress outcomes.
Dosing Protocols
Standard Dosing
The recommended dosage range for AGE is 600–1200 mg taken once daily. This range is supported by the majority of clinical trials demonstrating cardiovascular and immune benefits.
Dosing by Health Goal
Cardiovascular and Blood Pressure Support: 1200 mg/day or higher doses tend to produce the most robust blood pressure reductions (4–5 mmHg systolic) based on meta-analytic evidence. However, modest benefits appear even at lower doses.
Immune Support: 2.56–3.6 g/day (2560–3600 mg/day) has been used in immunological studies, showing enhanced NK cell activation and reduced inflammatory markers.
Athletic Performance: Endurance athletes have used 1.2–2.4 g/day (1200–2400 mg/day) with improvements in aerobic fitness.
Microvascular Function: 2400 mg/day for extended periods (12 months) demonstrated improvements in post-occlusive reactive hyperemia and cutaneous vascular conductance.
Timing and Administration
AGE is typically taken with meals to enhance absorption and minimize gastrointestinal discomfort. Taking it with food